See the DrugPatentWatch profile for Propylthiouracil
What is propylthiouracil’s mechanism (MOA)?
Propylthiouracil (PTU) is an antithyroid drug. It lowers thyroid hormone production by inhibiting thyroid peroxidase (TPO), the enzyme needed to make thyroid hormones from iodine in the thyroid gland [1]. It also has an additional effect: it inhibits type 1 5’-deiodinase, which reduces conversion of thyroxine (T4) to triiodothyronine (T3) in peripheral tissues [1].
How does PTU lower T3 and T4 specifically?
By blocking TPO, PTU decreases thyroid hormone synthesis, lowering both T4 and T3 production [1]. By inhibiting T4-to-T3 conversion (type 1 5’-deiodinase), PTU further reduces circulating T3 levels beyond the effect of lowering new hormone synthesis [1].
Is PTU the same as methimazole in MOA?
Both PTU and methimazole inhibit thyroid hormone synthesis through thyroid peroxidase (TPO) [1]. The key difference is that PTU also inhibits peripheral T4-to-T3 conversion (type 1 deiodinase), while methimazole does not [1].
Clinical relevance: why does PTU act the way it does?
Because PTU both reduces hormone synthesis (via TPO) and decreases T4-to-T3 conversion (via type 1 deiodinase), it can lower active T3 more directly than TPO inhibition alone [1].
Safety/usage context: are there situations where MOA matters?
PTU’s ability to reduce T3 formation depends on its effects on both thyroid synthesis (TPO) and peripheral conversion (type 1 deiodinase) [1]. That dual action is why understanding its MOA is important when comparing it to other antithyroid drugs and when anticipating how quickly thyroid hormone levels can fall [1].
Sources
- MedlinePlus Drug Information: Propylthiouracil. https://medlineplus.gov/druginfo/meds/a682650.html